Expert review of respiratory medicine最新文献_第9页

Advances in exhaled breath condensate markers for severe asthma management: a systematic review. 呼气冷凝水标记物在严重哮喘管理中的进展：系统综述。

Expert review of respiratory medicine Pub Date : 2025-06-30 DOI: 10.1080/17476348.2025.2522743

Claudia Gagliani, Paul Brinkman, Marco Del Riccio, Alida Benfante, Shahriyar Shahbazi Khamas, Anke-H Maitland-van der Zee, Stefania Principe, Nicola Scichilone

{"title":"Advances in exhaled breath condensate markers for severe asthma management: a systematic review.","authors":"Claudia Gagliani, Paul Brinkman, Marco Del Riccio, Alida Benfante, Shahriyar Shahbazi Khamas, Anke-H Maitland-van der Zee, Stefania Principe, Nicola Scichilone","doi":"10.1080/17476348.2025.2522743","DOIUrl":"10.1080/17476348.2025.2522743","url":null,"abstract":"Background: Severe asthma is a chronic respiratory disease posing challenges for clinicians and patients, increasing health-care costs and patients' poor quality of life. Advances in precision medicine have introduced novel approaches to managing severe asthma, including breathomics, a promising field using exhaled breath analysis to identify disease biomarkers. Among these techniques, exhaled breath condensate (EBC) analysis has emerged as a potential noninvasive tool for monitoring airway inflammation and disease progression.Methods: A systematic literature review was conducted to identify EBC biomarkers for monitoring severe asthma, searching across PubMed, Cochrane, Google Scholar, MEDLINE, ISRCTN, EMBASE and Web of Science.Results: Twenty-three studies were included in the review. Key markers identified were 8-isoprostane, hydrogen peroxide (H₂O₂), nitric oxide (NO), and eicosanoids. Among these, 8-isoprostane was the most widely studied biomarker in severe asthma, while H₂O₂ seems to be most closely linked to assessing asthma control.Conclusions: To the best of our knowledge, this is the first systematic review focusing on EBC biomarkers in severe asthma. Breath analysis represents a promising noninvasive approach to evaluate airway inflammation, identify early signs of poorly controlled asthma and monitor treatment response. Further research is needed to validate these biomarkers for clinical application.Protocol registration: uk/prospero with identifier CRD42023406669 https://www.crd.york.ac.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1-12"},"PeriodicalIF":0.0,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144328218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical trials on acute exacerbations of interstitial lung diseases. 肺间质性疾病急性加重的临床试验。

Expert review of respiratory medicine Pub Date : 2025-06-22 DOI: 10.1080/17476348.2025.2519861

Panagiota Tsiri, Fabiola Murgolo, Bruno Crestani

{"title":"Clinical trials on acute exacerbations of interstitial lung diseases.","authors":"Panagiota Tsiri, Fabiola Murgolo, Bruno Crestani","doi":"10.1080/17476348.2025.2519861","DOIUrl":"10.1080/17476348.2025.2519861","url":null,"abstract":"Introduction: Acute exacerbations in interstitial lung diseases, especially idiopathic pulmonary fibrosis, remain a significant clinical challenge associated with high mortality. Previously used empirical immunosuppressive therapies, notably cyclophosphamide, have proven ineffective.Areas covered: A literature search was conducted using the PubMed and ClinicalTrials.gov (NCT) databases for studies published up to March 2025. This review summarizes recent randomized clinical trial data on acute exacerbations, highlighting negative results for cyclophosphamide and recombinant thrombomodulin and positive preventive effects of antifibrotics such as nintedanib and pirfenidone. The evidence supporting vaccination strategies, methodological limitations in trial design, and diagnostic challenges are also discussed.Expert opinion: Shifting clinical practice away from harmful therapies toward precision medicine approaches, utilizing biomarkers, preventive antifibrotic strategies, and novel therapeutic targets, is essential. International collaboration in clinical research is crucial to improve patient outcomes.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1-10"},"PeriodicalIF":0.0,"publicationDate":"2025-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144319023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unlocking the secrets of success: enhancing non-invasive respiratory support therapies for improved patient outcomes. 解锁成功的秘密：加强无创呼吸支持治疗，改善患者预后。

Expert review of respiratory medicine Pub Date : 2025-06-12 DOI: 10.1080/17476348.2025.2518282

Lara Pisani, Sarah Heili, Begum Ergan, Patrick Murphy, Gilda Giancotti, Joao Carlos Winck

引用次数: 0

Advances and future outlook in clinical trials for treating systemic sclerosis-interstitial lung disease. 系统性硬化症-间质性肺疾病临床研究进展及展望

Expert review of respiratory medicine Pub Date : 2025-06-01 Epub Date: 2025-04-08 DOI: 10.1080/17476348.2025.2490729

Marzieh Jamali, Rocio Bautista Sanchez, Prachi Agarwal, Dinesh Khanna

{"title":"Advances and future outlook in clinical trials for treating systemic sclerosis-interstitial lung disease.","authors":"Marzieh Jamali, Rocio Bautista Sanchez, Prachi Agarwal, Dinesh Khanna","doi":"10.1080/17476348.2025.2490729","DOIUrl":"10.1080/17476348.2025.2490729","url":null,"abstract":"Introduction: Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is a common complication of systemic sclerosis (SSc), contributing significantly to morbidity and mortality. We aim to bridge knowledge gaps, inform clinical practice, and identify future research directions in this rapidly evolving field.Areas covered: This review provides a comprehensive analysis of the current understanding and emerging advances in the diagnosis, risk stratification, and treatment of SSc-ILD. High-resolution computed tomography (HRCT) and pulmonary function tests (PFTs) remain cornerstones of diagnosis, but limitations in sensitivity underscore the need for biomarkers such as Chemokine (C-C motif) Ligand 18 (CCL18), Krebs von den Lungen-6 (KL-6), Interleukin-6 (IL-6), and C-reactive protein (CRP) to enhance prognostic precision and treatment personalization. Therapeutic strategies emphasize immunosuppressants alongside antifibrotic agents. Emerging combination therapies and advanced modalities, including hematopoietic stem cell transplantation and chimeric antigen receptor T-cell therapy, show promise in refractory cases. Ongoing clinical trials exploring innovative targets highlight the evolving therapeutic landscape. The review emphasizes challenges in clinical trial design, advocating for adaptive and platform trial methodologies to address disease heterogeneity and enhance treatment sensitivity.Expert opinion: Advances in biomarkers, composite indices, and personalized therapeutic approaches are key to overcoming existing limitations and improving outcomes for patients with SSc-ILD.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"521-533"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143805192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Approaches to reduce the risk of severe asthma in children with preschool wheeze. 降低学龄前喘息儿童严重哮喘风险的方法。

Expert review of respiratory medicine Pub Date : 2025-06-01 Epub Date: 2025-04-12 DOI: 10.1080/17476348.2025.2491722

Andrew Bush, Bianca Schaub

{"title":"Approaches to reduce the risk of severe asthma in children with preschool wheeze.","authors":"Andrew Bush, Bianca Schaub","doi":"10.1080/17476348.2025.2491722","DOIUrl":"10.1080/17476348.2025.2491722","url":null,"abstract":"Introduction: Asthma is a common, serious condition. We can treat the symptoms of mild-moderate disease, but severe asthma is life-threatening despite treatment. We cannot cure asthma and have no specific preventive strategies.Areas covered: We performed a PubMed search using the terms 'Severe asthma' and 'Prevention' and 'Preschool wheeze' limited to children, humans and English language over the previous five years. We searched the bibliographies of relevant references and also our personal archives. We cover transgenerational, antenatal and early life factors which increase the risk of pre-school wheeze; the factors promoting or protecting the pre-school wheezer from developing school age asthma; and the factors leading to one of the three types of severe asthma defined by WHO (untreated, difficult to treat, and treatment resistant).Expert opinion: Currently we have no pharmacological preventive strategies. Risk can be reduced by public health measures such as reduction in smoking and environmental pollution, and there are tantalizing hints from comparison of farming to other environments that exploring how environmental modulation may lead to more specific, personalized strategies. The effects of the new RSV prevention strategies are awaited. We need a better understanding of the pathways driving disease progression, and biomarkers of risk.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"535-550"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144046185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Analysis and prediction of the burden of COPD in original BRICS countries from 1990 to 2050. 1990 年至 2050 年金砖五国原住民慢性阻塞性肺病负担分析与预测。

Expert review of respiratory medicine Pub Date : 2025-06-01 Epub Date: 2025-04-03 DOI: 10.1080/17476348.2025.2488961

Daidi Gui, Long Zhang, Chuting Wang, Wenjing Zou, Linxin Liu, Jinfeng He, Xinman Qian, Rui Ding

{"title":"Analysis and prediction of the burden of COPD in original BRICS countries from 1990 to 2050.","authors":"Daidi Gui, Long Zhang, Chuting Wang, Wenjing Zou, Linxin Liu, Jinfeng He, Xinman Qian, Rui Ding","doi":"10.1080/17476348.2025.2488961","DOIUrl":"10.1080/17476348.2025.2488961","url":null,"abstract":"Background: The Original BRICS countries (Brazil, Russia, India, China, and South Africa) face similar challenges of a significant increase in the burden of chronic obstructive pulmonary disease (COPD).Research design and methods: This analysis, based on data from the 2021 Global Burden of Disease (GBD 2021), examined trends in the incidence, mortality, and disability-adjusted life years (DALYs) rates of COPD in Original BRICS countries from 1990 to 2021. Linear regression was used to estimate the annual percentage change (EAPC) of age-standardized rates (ASR), and Bayesian age-period-cohort (BAPC) model was used to predict the COPD burden in 2050.Results: The disease burden increased with age in 2021, particularly after 45 years old, with significant gender disparities. From 1990 to 2021, the EAPC for age-standardized incidence, mortality, and DALYs rates decreased, with China experiencing the sharpest decline. The COPD burden is predicted to be alleviated across Original BRICS countries in 2050, although men will still be more affected than women.Conclusion: Despite the substantial improvements, the burden of COPD remains substantial in Original BRICS countries. In 2050, COPD is expected to more pronouncedly affect middle-aged and elderly populations, as well as people exposed to tobacco and environmental pollution.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"619-628"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143775132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Transforming pulmonary health care: the role of artificial intelligence in diagnosis and treatment. 转型肺部卫生保健：人工智能在诊断和治疗中的作用。

Expert review of respiratory medicine Pub Date : 2025-06-01 Epub Date: 2025-04-15 DOI: 10.1080/17476348.2025.2491723

Farzat Farha, Sageer Abass, Saba Khan, Javed Ali, Bushra Parveen, Sayeed Ahmad, Rabea Parveen

{"title":"Transforming pulmonary health care: the role of artificial intelligence in diagnosis and treatment.","authors":"Farzat Farha, Sageer Abass, Saba Khan, Javed Ali, Bushra Parveen, Sayeed Ahmad, Rabea Parveen","doi":"10.1080/17476348.2025.2491723","DOIUrl":"10.1080/17476348.2025.2491723","url":null,"abstract":"Introduction: Respiratory diseases like pneumonia, asthma, and COPD are major global health concerns, significantly impacting morbidity and mortality rates worldwide.Areas covered: A selective search on PubMed, Google Scholar, and ScienceDirect (up to 2024) focused on AI in diagnosing and treating respiratory conditions like asthma, pneumonia, and COPD. Studies were chosen for their relevance to prediction models, AI-driven diagnostics, and personalized treatments. This narrative review highlights technological advancements, clinical applications, and challenges in integrating AI into standard practice, with emphasis on predictive tools, deep learning for imaging, and patient outcomes.Expert opinion: Despite these advancements, significant challenges remain in fully integrating AI into pulmonary health care. The need for large, diverse datasets to train AI models is critical, and concerns around data privacy, algorithmic transparency, and potential biases must be carefully managed. Regulatory frameworks also need to evolve to address the unique challenges posed by AI in health care. However, with continued research and collaboration between technology developers, clinicians, and policymakers, AI has the potential to revolutionize pulmonary health care, ultimately leading to more effective, efficient, and personalized care for patients.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"575-595"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144033262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Can humidified high flow reverse mucus plugging? 加湿高流量能逆转粘液堵塞吗？

Expert review of respiratory medicine Pub Date : 2025-06-01 Epub Date: 2025-04-10 DOI: 10.1080/17476348.2025.2490715

Claudia Crimi, Santi Nolasco

引用次数: 0

Willingness to engage in self-care impacts clinical outcomes at discharge in hospitalized pneumonia patients: a descriptive study. 参与自我护理的意愿影响住院肺炎患者出院时的临床结果：一项描述性研究。

Expert review of respiratory medicine Pub Date : 2025-06-01 Epub Date: 2025-04-07 DOI: 10.1080/17476348.2025.2489735

María Granados-Santiago, Geraldine Valenza-Peña, Ana Belén Gámiz-Molina, Julia Raya-Benítez, Alejandro Heredia-Ciuró, Laura López-López, Marie Carmen Valenza

{"title":"Willingness to engage in self-care impacts clinical outcomes at discharge in hospitalized pneumonia patients: a descriptive study.","authors":"María Granados-Santiago, Geraldine Valenza-Peña, Ana Belén Gámiz-Molina, Julia Raya-Benítez, Alejandro Heredia-Ciuró, Laura López-López, Marie Carmen Valenza","doi":"10.1080/17476348.2025.2489735","DOIUrl":"10.1080/17476348.2025.2489735","url":null,"abstract":"Background: The objective of this study was to evaluate the association between willingness to engage in self-care and clinical outcomes in patients hospitalized with community-acquired pneumonia (CAP).Methods: An observational study in patients hospitalized with CAP was conducted. Patients were divided into two groups according to the willingness to engage in self-care, which was assessed with the Patient Activation Measure (PAM). Participants with scores ≤47.0 points were included in the unwillingness to engage in self-care group, and patients with PAM score >47 points were included in the willingness to engage in self-care group. Main variables were assessed at hospital discharge and included clinical symptoms (cough, dyspnea, pain, and fatigue), physical status, activity levels, psychological inflexibility and restrictions in daily life activities and social participation.Results: A total of 66 patients were included in the study (34 among the patients unwilling to engage and 32 among the patients willing to engage). Significant differences were found in clinical symptoms, psychological inflexibility, and restrictions in daily life activities and social participation in favor of patients' willingness to engage in self-care at hospital discharge.Conclusions: Patients with CAP willing to engage in self-care showed improvements in clinical symptoms, psychological flexibility, and fewer limitations in daily activities and social participation at discharge.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"629-634"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143782354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An overview of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. 球囊肺血管成形术治疗慢性血栓栓塞性肺动脉高压的综述。

Expert review of respiratory medicine Pub Date : 2025-06-01 Epub Date: 2025-04-21 DOI: 10.1080/17476348.2025.2491721

Keiichiro Kuronuma, Hiroto Shimokawahara, Hiromi Matsubara

{"title":"An overview of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension.","authors":"Keiichiro Kuronuma, Hiroto Shimokawahara, Hiromi Matsubara","doi":"10.1080/17476348.2025.2491721","DOIUrl":"10.1080/17476348.2025.2491721","url":null,"abstract":"Introduction: Chronic thromboembolic pulmonary hypertension (CTEPH) is a severe and progressive condition caused by unresolved pulmonary arterial obstructions, leading to secondary microvasculopathy and poor hemodynamics. Pulmonary endarterectomy (PEA) is the first-line treatment for operable patients. Balloon pulmonary angioplasty (BPA) has emerged as a promising treatment option for patients considered inoperable due to distal lesions, comorbidities, or residual pulmonary hypertension (PH) after PEA. Following the development of the BPA in safety and efficacy, it has been widely adopted and utilized across the globe.Areas covered: This review covers the historical development of BPA, its clinical role, and technical methodologies. Medical therapies as an adjunctive role in CTEPH management are also discussed. Finally, we present recent BPA experiences from our institution, highlighting hemodynamic outcomes and survival rates.Expert opinion: BPA is a transformative treatment for patients with CTEPH, particularly those ineligible for PEA. Procedural refinements have significantly improved safety and efficacy. However, challenges remain, including the standardization of decision-making processes for management and the establishment of optimal treatment goals. Ongoing research continues to refine the role of BPA to improve outcomes and enhance the quality of life for patients with CTEPH. [Figure: see text].","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"563-573"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144033198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0